Novel Targeted Agents for Lung Cancer: M7824, a Bifunctional Protein Targeting PD-L1 and TGB- β Receptor II

In a phase I trial, this first-in-class novel drug yielded a 71% response rate in very high expressers of PD-L1 treated at 1,200 mg every 2 weeks.

Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Luis G. Paz-Ares, MD Source Type: news